BRD4 and cancer: Recently, several potent small-molecule BRD4 inhibitors such as JQ1 and I-BET, which disrupt BET proteins binding to acetylated histones, have been discovered and have shown promising therapeutic potential in preclinical models of multiple cancers (Filippakopoulos et al., 2010; Filippakopoulos and Knapp 2014; Boi et al., 2015).